Overview
This review examines the evolving evidence base surrounding testosterone deficiency (TD) and testosterone therapy (TTh), challenging long-standing misconceptions regarding cardiovascular and prostate safety. Drawing on large observational studies, randomized trials, and mechanistic research, the authors argue that testosterone deficiency is a meaningful, independent risk factor for adverse health outcomes and that appropriate testosterone therapy provides substantial systemic benefits when used in properly diagnosed patients.

Key Findings

Testosterone Deficiency as a Health Risk
The authors identify testosterone deficiency as a clinically significant condition associated with increased all-cause mortality, cardiovascular disease, metabolic syndrome, type 2 diabetes, anemia, sarcopenia, osteoporosis, sexual dysfunction, and reduced quality of life. Evidence suggests TD is not merely a biomarker of poor health, but an active contributor to disease progression.

Cardiovascular Health and Mortality
Contrary to earlier concerns, the review highlights robust evidence showing that testosterone therapy does not increase cardiovascular risk when prescribed appropriately. Multiple large-scale observational studies demonstrate that men whose testosterone levels are restored to physiological ranges experience lower rates of myocardial infarction, stroke, atrial fibrillation, and all-cause mortality compared to untreated hypogonadal men or those whose levels remain low despite therapy.

Metabolic and Glycemic Effects
Testosterone plays a key role in metabolic regulation. The review summarizes evidence showing that testosterone therapy improves insulin sensitivity, reduces visceral adiposity, improves lipid profiles, and lowers progression to type 2 diabetes. In some studies, long-term testosterone therapy was associated with diabetes remission and reduced dependence on glucose-lowering medications.

Musculoskeletal and Hematologic Benefits
Testosterone therapy supports lean muscle mass, strength, bone density, and physical function, while also correcting anemia through stimulation of erythropoiesis. These effects are particularly relevant in aging men and those with chronic disease.

Prostate Health Reconsidered
The authors address historical concerns linking testosterone therapy to prostate cancer, noting that contemporary evidence does not support an increased risk. Emerging data suggest that maintaining normal testosterone levels may be neutral or even protective against aggressive prostate cancer when therapy is appropriately monitored.
Importance of Testosterone Normalization
A consistent theme throughout the review is that restoration to physiologic testosterone levels—rather than partial treatment or symptom-only management—is associated with the most favorable outcomes. Men whose testosterone remains low despite treatment do not experience the same reductions in morbidity or mortality.

Clinical Considerations

The authors emphasize that testosterone therapy should be reserved for men with documented testosterone deficiency and managed with appropriate monitoring. They advocate for greater clinical awareness of TD as a modifiable risk factor and call for updated clinical guidelines that reflect the growing body of evidence supporting the safety and value of testosterone therapy.

Conclusion
This review argues that testosterone deficiency is a significant, underrecognized contributor to poor health outcomes in men and that appropriately prescribed testosterone therapy offers broad systemic benefits. The authors conclude that restoring testosterone to physiological levels can improve metabolic, cardiovascular, musculoskeletal, and overall health outcomes, and should be considered an important component of modern men’s health care.